Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding

Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2003, Pages 1031-1040

  Muth, Mathias ^a   Bender, Wiebke ^a   Scharfenstein, Olaf ^a   Holzgrabe, Ulrike ^a   Balatkova, Edith ^b   Tränkle, Christian ^b   Mohr, Klaus ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANE DERIVATIVE; AMMONIUM DERIVATIVE; METHYLSCOPOLAMINE; MUSCARINIC M2 RECEPTOR;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; DISSOCIATION; DRUG STRUCTURE; DRUG SYNTHESIS; LIGAND BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SWINE;

ALKANES; ALLOSTERIC REGULATION; ANIMALS; LIGANDS; MYOCARDIUM; PHTHALIC ACIDS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUATERNARY AMMONIUM COMPOUNDS; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M2; RECEPTORS, MUSCARINIC; REGRESSION ANALYSIS; SWINE;

EID: 0037435052     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021017q     Document Type: Article

References (45)

1. Christopoulos, A.; Kenakin, T. G-Protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 2002, 54, 323-374.
2. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discuss. 2002, 1, 198-210.
3. Lazareno, S.; Birdsall, N. J. M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G-Protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 1995, 48, 362-378.
4. Tucek, S.; Proška, J. Allosteric modulation of muscarinic acetylcholine receptors. Trends Pharmacol. Sci. 1995, 16, 205-212.
5. Ellis, J. Allosteric binding site on muscarinic receptors. Drug Dev. Res. 1997, 40, 193-204.
6. Christopoulos, A.; Lanzafame, A.; Mitchelson, F. Allosteric interactions at muscarinic cholinoceptors. Clin. Exp. Pharmacol. Phys. 1998, 25, 185-194.
7. Holzgrabe, U.; Mohr, K. Allosteric modulation of antagonist binding to muscarinic receptors. Drugs Discovery Today 1998, 3, 214-222.
8. Soudijn, W.; van Wijngaarden, I.; Ijzerman, A. P. Allosteric modulation of G-protein-coupled receptors. Expert Opin. Ther. Patents 2001, 11, 1889-1904.
9. 2 muscarine receptors. Mol. Pharmacol. 1994, 46, 105-114.
10. Tränkle, C.; Kostenis, E.; Burgmer, U.; Mohr, K. Search for lead structures to develop new allosteric modulators of muscarinic receptors. J. Pharmacol. Exp. Ther. 1996, 279, 926-933.
11. Ellis, J.; Seidenberg, M. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol. Pharmacol. 1992, 42, 638-641.
12. Stockton, J. M.; Birdsall, N. J. M.; Burgen, A. S. V.; Hulme, E. C. Modification of the binding properties of the muscarinic receptors by gallamine. Mol. Pharmacol. 1983, 23, 551-557.
13. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand and pharmacological null methods. Mol. Pharmacol. 1988, 83, 187-194.
14. Proska, J.; Tucek, S. Mechanism of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 1994, 45, 709-717.
15. Buller, S.; Zlotos, D. P.; Mohr, K.; Ellis, J. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derrivatives and alkane-bisammonium ligands. Mol. Pharmacol. 2002, 61, 160-168.
16. Waelbroeck, M.; Robberecht, P.; De-Neef, P.; Christophe, J. Effects of d-tubocurarine on rat muscarinic receptors. J. Recept. Res. 1988, 8, 787-808.
17. Waelbroeck, M. Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol. Pharmacol. 1994, 46, 685-692.
18. Giraldo, E.; Micheletti, R.; Montagna, E.; Giachetti, A.; Vigano, M. A.; Ladinsky, M.; Melchiorre, C. Binding and functional characterization of the cardioselective muscarinic antagonist methoctramine. J. Pharmacol. Exp. Ther. 1988, 244, 1016-1020.
19. 3H-N-methylscopolamine binding in guinea-pig myocardium by an antidote against organophosphorus intoxication. Pharmacol. Toxicol. 1988, 63, 163-168.
20. 2 receptors. Mol. Pharmacol. 1998, 54, 139-145.
21. 2-cholinoceptors. J. Pharm. Pharmacol. 1994, 46, 108-112.
22. 2 acetylcholine receptors: optimization of the distances between the pharmacophoric elements. J. Med. Chem. 1999, 42, 849-858.
23. 2-receptors. Life Sci. 1998, 62, 423-429.
24. 2-receptor allosterically. J. Med. Chem. 2000, 43, 2155-2164.
25. 2-receptors. Life Sci. 2000, 66, 1675-1682.
26. 2-cholinoceptors. Pharm. Pharmacol. Lett. 1992, 2, 100-103.
27. Kostenis, E.; Botero Cid, H. M.; Holzgrabe, U.; Mohr, K. Evidence for a multiple binding mode of bispyridinium-type allosteric modulators of muscarinic receptors. Eur. J. Pharmacol. 1996, 314, 385-392.
28. 2 acetylcholine receptors by bis(ammonio)alkane-type allosteric modulators. J. Med. Chem. 2002, 45, 3809-3812.
29. 2 receptors: synthesis, allosteric potency, and positive cooperativity of silicon-based W84 derivatives. Organometallics 2002, 21, 803-811.
30. Contractor, R. B.; Peters, A. T. New intermediates and dyes. Part I. 4-Tert.-butylphthalic acid and its anhydrides J. Chem. Soc., Perkin Trans. 2 1949, 1314.
31. Larner, B. W.; Peters, A. T. New intermediates and dyes. Part II. Preparation and properties of 4-tert.-butylphthalic anhydride. Orientation of its condensation products with benzoid hydrocarbons. J. Chem. Soc., Perkin Trans. 1 1952, 680-686.
32. Lombardino, J. G. Unusual dimeric salts of 2-(3-pyridyl)-1,3-indandione. J. Org. Chem. 1967, 32, 1988-1992.
33. Pawlowski, G.; Hanack, M. A. A convenient synthesis of trifluormethyl substituted phthalocyanines. Synth. Commun. 1981, 11, 351-363.
34. 2 receptor binding of the selective antagonist AF-DX 384: possible involvement of the common allosteric site. Mol. Pharmacol. 1998, 53, 304-312.
35. Christopoulos, A. Assessing the distribution of parameters in models of ligand-receptor interaction: to log or not to log. Trends Pharmacol. Sci. 1998, 19, 351-357.
36. Kostenis, E.; Mohr, K. Composite action of allosteric modulators on ligand binding. Trends Pharmacol. Sci. 1996, 17, 443-444.
37. Kubinyi, H. QSAR: Hansch analysis and related approaches; VCH: Weinheim, 1993.
38. Holzgrabe, U.; Wagener, M.; Gasteiger, J. Comparison of structurally different allosteric modulators of muscarinic receptors by self-organizing neural networks. J. Mol. Graphics 1996, 14, 185-193.
39. Holzgrabe, U.; Hopfinger, A. J. Conformational analysis, molecular shape comparison, and pharmacophore identification of different allosteric modulators of muscarinic receptors. J. Chem. Inf. Comput. Sci. 1996, 36, 1018-1024.
40. Stiefl, N.; Baumann, K.; MaP: A novel 3D QSAR technique based on the distribution of molecular surface properties. J. Med. Chem. 2002, accepted.
41. 2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 363-370.
42. Lysíková, M.; Havlas, Z.; Turek, S. Interaction between allosteric modulators and 4-DAMP and other antagonists at muscarinic receptors: potential significance of the distance between the N and carboxyl C atoms in the molecules of antagonists. Neurochem. Res. 2001, 26, 383-394.
43. Tränkle, C.; Mohr, K. Divergent modes of action among cationic allosteric modulators of muscarinic receptors. Mol. Pharmacol. 1997, 51, 674-682.
44. Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
45. Kubinyi, H., BASF AG, 67056 Ludwigshafen, Germany, 1997.